Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Funding Rounds (2) - $5.1MUpdate
Wilmington Investor Network is private equity fund of angel investors located in Wilmington ,...
The largest angel investor network
Professional Angel Investors
BlueTree Allied Angels is a regional group of accredited investors who invest in regional...
Premier angel investment group
409 Illinois Street, Suite 4004
San Francisco, CA 94158